Guggenheim analyst Subbu Nambi initiated coverage of NeoGenomics (NEO) with a Neutral rating.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target lowered to $12 from $18 at Piper Sandler
- NeoGenomics, Sherwin-Williams, Grab, Paccar, First Solar: Trending by Analysts
- NeoGenomics: Hold Rating Amid Mixed Performance and Uncertain MRD Pathway
- NeoGenomics price target lowered to $10 from $17 at Morgan Stanley
- NeoGenomics price target lowered to $12 from $17 at TD Cowen